Novacyt (ALNOV) - Total Liabilities

Latest as of June 2025: €22.08 Million EUR ≈ $25.82 Million USD

Based on the latest financial reports, Novacyt (ALNOV) has total liabilities worth €22.08 Million EUR (≈ $25.82 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Novacyt cash flow conversion to assess how effectively this company generates cash.

Novacyt - Total Liabilities Trend (2008–2024)

This chart illustrates how Novacyt's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Novacyt to evaluate the company's liquid asset resilience ratio.

Novacyt Competitors by Total Liabilities

The table below lists competitors of Novacyt ranked by their total liabilities.

Company	Country	Total Liabilities
Green Critical Minerals Ltd AU:GCM	Australia	AU$592.06K
Marco Holdings Bhd KLSE:3514	Malaysia	RM18.83 Million
KD Chem Co. Ltd KQ:221980	Korea	₩30.42 Billion
GeneBioTech Co. Ltd KQ:086060	Korea	₩21.41 Billion
Wulff-Yhtiot Oy HE:WUF1V	Finland	€38.10 Million
The Peria Karamalai Tea & Produce Company Limited NSE:PKTEA	India	Rs617.51 Million
Manaksia Aluminium Company Limited NSE:MANAKALUCO	India	Rs3.96 Billion

Liability Composition Analysis (2008–2024)

This chart breaks down Novacyt's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Novacyt.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	5.03	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	3.54	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.54	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.35	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novacyt's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novacyt (2008–2024)

The table below shows the annual total liabilities of Novacyt from 2008 to 2024.

Year	Total Liabilities	Change
2024-12-31	€22.75 Million ≈ $26.60 Million	-51.15%
2023-12-31	€46.57 Million ≈ $54.45 Million	+81.32%
2022-12-31	€25.68 Million ≈ $30.03 Million	-38.67%
2021-12-31	€41.88 Million ≈ $48.96 Million	-49.88%
2020-12-31	€83.57 Million ≈ $97.70 Million	+493.86%
2019-12-31	€14.07 Million ≈ $16.45 Million	+26.14%
2018-12-31	€11.16 Million ≈ $13.04 Million	+37.94%
2017-12-31	€8.09 Million ≈ $9.45 Million	-25.14%
2016-12-31	€10.80 Million ≈ $12.63 Million	+122.45%
2015-12-31	€4.86 Million ≈ $5.68 Million	+2.56%
2014-12-31	€4.74 Million ≈ $5.54 Million	+555.79%
2013-12-31	€722.07K ≈ $844.18K	-63.13%
2012-12-31	€1.96 Million ≈ $2.29 Million	-2.26%
2011-12-31	€2.00 Million ≈ $2.34 Million	-27.02%
2010-12-31	€2.75 Million ≈ $3.21 Million	+6.77%
2009-12-31	€2.57 Million ≈ $3.01 Million	+34.66%
2008-12-31	€1.91 Million ≈ $2.23 Million	--

About Novacyt

PA:ALNOV France Medical Devices

Market Cap

$26.46 Million

€22.64 Million EUR

Market Cap Rank

#24136 Global

#394 in France

Share Price

€0.32

Change (1 day)

-13.38%

52-Week Range

€0.32 - €0.72

All Time High

€13.24